Abstract
The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model. Bone samples from 35 patients with ONJ were analyzed. Control samples were taken from five patients with osteomyelitis (OM), ten patients with osteoradionecrosis, seven patients with osteoporosis and bisphosphonate medication without signs of ONJ, and six osteoporotic elderly patients. Samples were examined using scanning electron microscopy. In 54% of the bone samples of patients with ONJ, microcracks were seen. Inflammatory and connective tissue reactions within the microcracks were evident in 82% of the cases, indicating that these cracks were not artificial. In contrast, only 29% of samples from patients with oral bisphosphonate medication without ONJ, no sample from patients with OM, none of the osteoradionecrosis group, and only 17% from patients with osteoporosis showed microcracks. Statistically significant differences could be found between the ONJ group and the group after irradiation and the group with OM, respectively. The evidence of microcracks could be a first step in the pathogenesis of bisphosphonate-related ONJ. The accumulation of these microcracks leads to a situation that could be named “non-symptomatic ONJ”. Disruptions of the mucosal integrity may then allow bacterial invasion, leading to jawbone infection with exposed bone, fistulas, and pain. This state could be called “symptomatic ONJ”. Furthermore, an assumed local immunosuppression as indicated by various studies could explain the severe courses of therapy-resistant ONJ as regularly observed.
Similar content being viewed by others
References
Abu-Id MH, Acil Y, Gottschalk J, Kreusch T (2006) Bisphosphonatassoziierte Osteonekrose des Kiefers. Mund Kiefer Gesichtschir 10:73–81
Allen MR, Burr DB (2008) Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 66:987–994
Altundal H, Guevener OE (2004) The effect of alendronate on resorption of the alveolar bone following tooth extraction. Int J Oral Maxillofac Surg 33:286–293
Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945–952
Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Papadimitriou C, Terpos E, Dimopoulos A (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587
Bouvier M, Hylander WL (1981) Effect of bone strain on cortical bone structure in macaques (Macaca mulatta). J Morph 167:1–12
Bras J, de Jonge HKT, van Merkensteyn JPR (1990) Osteoradionecrosis of the mandible: pathogenesis. Am J Otolaryngol 11:244–250
Bukowski JF, Dascher CC, Das H (2005) Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun 328:746–750
Burr DB, Hooser M (1995) Alterations to the en bloc basic fuchsin staining protocol for the demonstration of microdamage produced in vivo. Bone 17:431–433
Burr DB, Stafford T (1990) Validity of the bulk staining technique to separate artificial from in vivo bone microdamage. Clin Orthop Relat Res 260:305–308
Burr DB, Martin RB, Schaffler MB, Radin EL (1985) Bone remodeling in response to in vivo fatigue microdamage. J Biomech 18:189–200
Conti L, Casetti R, Cardone M, Varano B, Martino A, Belardelli F, Poccia F, Gessani S (2005) Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol 174:252–260
Day JS, Ding M, Bednarz P, van der Linden JC, Mashiba T, Hirano T, Johnston CC, Burr DB, Hvid I, Sumner DR, Weinans H (2004) Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties. J Orthop Res 22:465–471
Dechow PC, Hylander WL (2000) Elastic properties and masticatory bone stress in the macaque mandible. Am J Phys Anthropol 112:553–574
Dicuonzo G, Vincenzi B, Santini D, Avvisati L, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola R, Tonini G (2003) Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 23:649–654
Dieli F, Gebbia N, Poccia F, Gaccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C, Sireci G, Salerno A (2003) Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102:2310–2311
Enzendam J, Kosterman K, Spijkerboer H, Bleumink R, Hassing I, van Rooijen N, Vos JG, Pieters R (2005) Macrophages are involved in hexachlorobenzene-induced adverse effects. Toxicol Appl Pharmacol 209:19–27
Frost HM (1960) Presence of microscopic cracks in vivo in bone. Henry Ford Hosp Med Bull 8:25–35
Hansen T, Kunkel M, Kirkpatrick CJ, Weber A (2006) Actimomyces in infected osteoradionecrosis—underestimated? Human Pathol 37:61–67
Hansen T, Kunkel M, Weber A, Kirkpatrick CJ (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates—histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35:155–160
Hansen T, Wagner W, Kirkpatrick CJ, Kunkel M (2006) Infected osteoradionecrosis of the mandible: follow-up study suggests deterioration in outcome for patients with actinomyces-positive bone biopsies. Int J Oral Maxillofac Surg 35:1001–1004
Hellstein JW, Marek CL (2005) Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63:682–689
Hess LM, Jeter NJ, Benham-Hutchins M, Alberts DS (2008) Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 121:475–483
Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobishosphonates is inhibited by statins. Clin Exp Immunol 139:101–111
Hoefert S, Eufinger H (2006) Nekrosen der Kieferknochen unter Bisphosphonattherapie. Orthopäde 35:204–209
Hoefert S, Wierich W, Eufinger H, Krempien B (2006) BP-associated avascular necrosis (AN) of the jaws: histological findings. Bone 38(Suppl):76
Hu JH, Ding M, Soballe K, Bechtold JE, Danielsen CC, Days JS, Hvid I (2002) Effects of short-term alendronate treatment on the three-dimensional microstructural, physical, and mechanical properties of dog trabecular bone. Bone 31:591–597
Huja SS, Hasan MS, Pidaparti R, Turner CH, Garetto LP, Burr DB (1999) Development of a fluorescent light technique for evaluating microdamage in bone subjected to fatigue loading. J Biomech 32:1243–1249
Huk OL, Zukor DJ, Antoniou J, Petit A (2003) Effect of pamidronate on the stimulation of macrophage TNF-alpha release by ultra-high-molecular-weight polyethylene particles: a role for apoptosis. J Orthop Res 21:81–87
Jereczek-Fossa BA, Orechia R (2002) Radiotherapy-induced mandibular bone complications. Cancer Treat Rev 28:65–74
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Lillian Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of the task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491
Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha LA, Raghavan S (2008) Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66:839–847
Lee TC, Mohsin S, Taylor D, Parkesh R, Gunnlaugsson T, O’Brien FJ, Giehl M, Gowin W (2003) Detecting microdamage in bone. J Anat 203:161–172
Leemans JC, Juffermans NP, Florquin S, van Rooijen N, Vervoordeldank MJ, Verbon A, Deventer SJH, van der Poll T (2001) Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol 166:4604–4611
Li J, Mashiba T, Burr DB (2001) Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Cacif Tissue Int 69:281–286
Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1118
Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575
Mendenhall WM (2004) Mandibular osteoradionecrosis. J Clin Oncol 22:4867–4868
Migliorati CA (2003) Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21:253–254
Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Sook-Bin MS (2005) Managing the care of patients with bisphosphonate-associated osteonecrosis. An American academy of oral medicine position paper. JADA 136:1658–1668
Moreau MF, Guillet C, Massin P, Chavalier S, Gascan H, Basle MF, Chapparad D (2007) Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol 73:718–723
O’Brien FJ, Brennan O, Kennedy OD, Lee C (2005) Microcracks in cortical bone: how do they affect bone biology? Curr Osteoporos Rep 3:39–45
Odvina CV, Zerwkh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301
Ott SM (2005) Editoral: long-term safety of bisphosphonates. J Clin Endocrinol Metab 90:1897–1899
Papapoulos SE (2001) Catabolic and anabolic signals in bone: therapeutic implications. Curr Opin Clin Nutr Metab Care 4:191–196
Peleg M, Lopez EAL (2006) The treatment of osteoradionecrosis of the mandible: the case for hyperbaric oxygen and bone graft reconstruction. J Oral Maxillofac Surg 64:956–960
Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphophonates and calcitonin. J Clin Invest 104:1363–1374
Reid IR, Bolland MJ, Grey AB (2007) Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 47:318–320
Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42:841–847
Ruggiero SL, Mehrotra B, Rosenberg T, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534
Ruggiero SL, Fantasia J, Carlson E (2006) Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:433–441
Sarin J, DeRossi SS, Akintoye SO (2008) Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 14:277–285
Schaffler MB, Pitchford K, Choi K, Riddle M (1994) Examination of compact bone microdamage using back-scattered electron microscopy. Bone 15:483–488
Sedghizadeh PP, Kumar SKS, Gorur A, Schaudinn C, Shuler CF, Costerton JW (2008) Identification of microbiofilms in osteonecrosis of the jaws secondary to bisphosphonte therapy. J Oral Maxillofac Surg 66:767–775
Takagi K, Takagi M, Kanangat S, Warrington KJ, Shigemitsu H, Postlethwaite AE (2005) Modulation of TNF-alpha gene expression by IFN-gamma and pamidronate in murine macrophages: regulation by STAT1-dependent pathways. J Immunol 174:1801–1810
van Poznak C (2006) The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer. Cancer Invest 24:110–112
Wannfors K, Hammarström L (1985) Infectious foci in chronic osteomyelitis of the jaws. Int J Oral Surg 14:493–503
Acknowledgements
We would like to thank Burkhard Krempien (MD, PhD), professor emeritus of the Institute of Pathology, University of Heidelberg, Heidelberg, Germany, who first mentioned the importance of the microcracks seen in jaws under BP medication after his histological examinations of some specimen of our patients and also Walter Wierich (MD, PhD), Institute of Pathology, Recklinghausen, Germany, for his technical support and some important hints.
Conflicts of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hoefert, S., Schmitz, I., Tannapfel, A. et al. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Invest 14, 271–284 (2010). https://doi.org/10.1007/s00784-009-0300-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00784-009-0300-6